Vivo Capital is a healthcare focused investment firm formed in 1996 with over $3 billion under management. Vivo Capital is currently making investments from its $750M eighth fund into promising private and public healthcare companies in the U.S. and Greater China, from its $635M Opportunity fund into promising public healthcare companies, and from its $100M PANDA fund into promising early-stage innovative healthcare companies.

Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising therapeutic products at all stages in the U.S. and revenue stage companies in Greater China. Vivo Capital has offices in Palo Alto, California, Beijing, Shanghai and Taipei.

With extensive scientific expertise and operating experience in healthcare, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth. Vivo’s current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.